Preoperative Bevacizumab for Vitreous Hemorrhage

University of Sao Paulo16 enrolled

Overview

The purpose of this study is to determine whether preoperative intravitreal bevacizumab is effective in reducing intra-operative and postoperative bleeding in diabetic patients submitted to pars plana vitrectomy for vitreous hemorrhage.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Retinopathy Vitreous Hemorrhage

Interventions

bevacizumabDRUG

Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline

pars plana vitrectomyPROCEDURE

4 weeks after baseline

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetic retinopathy causing significant vitreous hemorrhage with visual acuity loss lasting more than three months in patients not previously treated and four months in those previously LASER treated. Exclusion Criteria: * Previous intra-ocular surgery other than cataract surgery * Retinal detachment * Use of anticoagulants drugs other than aspirin * Vitreous hemorrhage clearance at week-3 study period * History of previous thromboembolic events

Locations (1)

Clinics Hospital of Ribeirão Preto, School of Medicine of Ribeirão Preto, USP

Ribeirão Preto, São Paulo, Brazil

Outcomes

Primary Outcomes

Intra- and postoperative intra-ocular bleeding

Time frame: 12 weeks

Secondary Outcomes

Visual acuity

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.